EA202193111A1 - Композиции и способы для лечения рака - Google Patents

Композиции и способы для лечения рака

Info

Publication number
EA202193111A1
EA202193111A1 EA202193111A EA202193111A EA202193111A1 EA 202193111 A1 EA202193111 A1 EA 202193111A1 EA 202193111 A EA202193111 A EA 202193111A EA 202193111 A EA202193111 A EA 202193111A EA 202193111 A1 EA202193111 A1 EA 202193111A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
cancer
subject
compositions
treatment
Prior art date
Application number
EA202193111A
Other languages
English (en)
Inventor
Стивен Хоффман
Original Assignee
Тайм, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тайм, Инк. filed Critical Тайм, Инк.
Publication of EA202193111A1 publication Critical patent/EA202193111A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение представляет способы лечения рака. Настоящее изобретение относится к способам лечения рака путем увеличения окислительного стресса в раковой клетке. В частности, настоящее изобретение относится к способам лечения рака у субъекта, включающим снижение запасов гликогена у субъекта и введение субъекту эффективного количества производного тирозина.
EA202193111A 2019-05-14 2020-05-14 Композиции и способы для лечения рака EA202193111A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847570P 2019-05-14 2019-05-14
PCT/US2020/032847 WO2020232227A1 (en) 2019-05-14 2020-05-14 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
EA202193111A1 true EA202193111A1 (ru) 2022-02-10

Family

ID=73245256

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193111A EA202193111A1 (ru) 2019-05-14 2020-05-14 Композиции и способы для лечения рака

Country Status (12)

Country Link
US (1) US11534420B2 (ru)
EP (1) EP3968785A4 (ru)
JP (1) JP2022532210A (ru)
KR (1) KR20220098682A (ru)
CN (1) CN114173578A (ru)
AU (1) AU2020276605A1 (ru)
BR (1) BR112021022784A2 (ru)
CA (1) CA3140042A1 (ru)
EA (1) EA202193111A1 (ru)
IL (1) IL287982A (ru)
MX (1) MX2021013901A (ru)
WO (1) WO2020232227A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3140042A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
EP4045027A1 (en) * 2019-10-15 2022-08-24 Tyme, Inc. Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
CA3167918A1 (en) * 2020-01-17 2021-07-22 Tyme, Inc. Compositions and methods for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2022120039A2 (en) * 2020-12-02 2022-06-09 Steven Hoffman Compositions and methods for modulating cancer in non-human mammals

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029547A (en) 1974-07-01 1977-06-14 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
US4165382A (en) 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4117161A (en) 1977-05-16 1978-09-26 Jose Pozuelo Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
US4389415A (en) 1978-01-24 1983-06-21 Merck & Co., Inc. Method of treating hypertension
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
GB8706313D0 (en) 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
DE8907335U1 (de) 1989-06-15 1990-10-18 Espe Stiftung & Co Produktions- und Vertriebs KG, 8031 Seefeld Mischvorrichtung für Pasten
IL94914A (en) 1989-06-30 1994-07-31 Richter Gedeon Vegyeszet Acid separation.
US5029760A (en) 1989-10-26 1991-07-09 Gamblin Rodger L Centrifugal grinding and mixing apparatus
JPH03161442A (ja) 1989-11-21 1991-07-11 Chiyouseidou Seiyaku Kk コール酸又はそのナトリウム塩からなる脳代謝改善剤
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
US5310539A (en) 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
DE59307395D1 (de) 1992-07-08 1997-10-23 Dianorm G Maierhofer Gmbh Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels
DE4342174C1 (de) 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
CA2249299C (en) 1996-03-22 2004-02-17 Mayo Foundation For Medical Education And Research Combination of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum
US5733926A (en) 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
IT1291633B1 (it) 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
US5952374A (en) 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
EP1119252A4 (en) 1998-08-21 2004-03-03 Childrens Medical Center USE OF MELANIN FOR INHIBITING ANGIOGENESIS AND MACULAR DEGENERATION
DE19906977C1 (de) 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
JP2002196006A (ja) 2000-12-27 2002-07-10 Olympus Optical Co Ltd 自動分析装置
EP2269603B1 (en) 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
WO2002098403A1 (en) 2001-06-01 2002-12-12 Georgetown University Steroid hormone and non-steroidal anti-inflammatory drug combinations for inducing tumor cell apoptosis
JP4609875B2 (ja) 2001-07-31 2011-01-12 有限会社大長企画 健康食品
US7338971B2 (en) 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
JP4091557B2 (ja) 2003-03-18 2008-05-28 株式会社マンダム 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
KR20060135729A (ko) 2004-01-29 2006-12-29 백스터 인터내셔널 인코포레이티드 중추신경계 전달 증가를 위한 항레트로바이러스제의나노현탁액
WO2005072061A2 (en) 2004-02-02 2005-08-11 Biosight Ltd. Conjugates for cancer therapy and diagnosis
EP1674081A1 (de) 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
WO2006099685A1 (en) 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
EP1865955A4 (en) 2005-03-25 2009-04-15 Merck & Co Inc TREATMENT OF MALE-HUMAN HUMANS BY TESTOSTERONE SUPPLEMENTATION ASSOCIATED WITH 5ALPHA-REDUCTASE INHIBITOR
US20060223877A1 (en) 2005-03-31 2006-10-05 Zemlan Frank P Methods of treatment utilizing certain melatonin derivatives
CN101296691B (zh) 2005-08-05 2011-07-27 努沃研究公司 透皮释药剂型
JP5308160B2 (ja) 2005-11-15 2013-10-09 景▲かい▼ 程 前立腺疾病及び皮膚癌におけるイソチオシアネート系化合物の使用
KR20090014164A (ko) 2006-04-19 2009-02-06 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 세포 영상화 및 치료를 위한 조성물 및 방법
EP1884243A1 (en) 2006-05-02 2008-02-06 Charité - Universitätsmedizin Berlin Use of an antipsychotic drug for the treatment of ALS-associated cachexia
CN101138634A (zh) 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
US20100239661A1 (en) 2006-10-26 2010-09-23 Sunilendu Bhushan Roy Pharmaceutical compositions of ursodiol
WO2009152518A1 (en) 2008-06-13 2009-12-17 Wisconsin Alumni Research Foundation Novel peptide adjuvant for influenza vaccination
EP2208497A1 (en) 2009-01-15 2010-07-21 Charité-Universitätsmedizin Berlin (Charité) Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient
US20170029892A1 (en) 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
US20140018354A9 (en) 2009-07-23 2014-01-16 Nathaniel Moorman Inhibitors of mtor kinase as anti-viral agents
US20110118528A1 (en) * 2009-10-22 2011-05-19 University Of Southern California Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment
US8841486B2 (en) 2009-10-30 2014-09-23 Aton Pharma Stereoselective synthesis of metyrosine
KR101131675B1 (ko) 2010-01-28 2012-03-28 조선대학교산학협력단 우루소데옥시콜린산을 유효성분으로 함유하는 위암의 예방 또는 치료용 조성물
EP2558102A4 (en) 2010-04-16 2013-09-25 Davos Life Science Pte Ltd SYNERGISTIC INTERACTION OF AT LEAST ONE COMPONENT OF VITAMIN E AND TYROSINASE INHIBITORS FOR DERMATOLOGICAL APPLICATIONS
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
PL220308B1 (pl) 2011-06-03 2015-10-30 Kobel Buys Krystyna Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego
CN102397550B (zh) 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
WO2013096870A1 (en) 2011-12-22 2013-06-27 Knopp Neurosciences Inc Compositions and methods for treating amyotrophic lateral sclerosis
KR101480280B1 (ko) 2012-01-06 2015-01-14 주식회사 대웅제약 타우로우루소데옥시콜릭산을 포함하는 조성물
US20210386832A1 (en) 2012-01-17 2021-12-16 Tyme, Inc. Pharmaceutical Compositions And Methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
AU2013209862A1 (en) * 2012-01-17 2014-09-04 Tyme, Inc. Pharmaceutical compositions and methods
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US20150072967A1 (en) 2012-03-20 2015-03-12 Metselex, Inc. Tauroursodeoxycholic acid attentuates or abolishes formation and deposition of amyloid-b peptide
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
GB201216800D0 (en) 2012-09-20 2012-11-07 Immodulon Therapeutics Ltd Novel use
EP2919807B1 (en) 2012-11-16 2018-07-11 Finzi, Eric Treatment of post-traumatic stress disorder using botulinum toxin a
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
WO2015005419A1 (ja) 2013-07-11 2015-01-15 株式会社ポーラファルマ 使用時泡状を呈する外用組成物
US20170080093A1 (en) 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9724657B2 (en) 2013-10-22 2017-08-08 Tyme, Inc. High-speed centrifugal mixing devices and methods of use
US20150111878A1 (en) 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
CN103919787A (zh) 2014-04-17 2014-07-16 厦门大学 牛磺熊脱氧胆酸及其可接受的盐的制药用途
AU2015287749B2 (en) 2014-07-11 2021-03-11 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
CN106794188B (zh) 2014-09-28 2022-12-02 华辉安健（北京）生物科技有限公司 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
GB201419257D0 (en) 2014-10-29 2014-12-10 Jagotec Ag Pharmaceutical compositions
US9687528B2 (en) 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
EP3237013B1 (en) 2014-12-23 2023-06-07 Steven Hoffman Transdermal formulations
CN106031731A (zh) 2015-03-18 2016-10-19 中国医学科学院基础医学研究所 牛磺熊去氧胆酸的新用途
KR20180015126A (ko) 2015-04-14 2018-02-12 스티븐 호프만 자폐증을 치료하기 위한 조성물 및 방법
WO2017117158A1 (en) 2015-12-28 2017-07-06 Steven Hoffman Methods of treating amyotrophic lateral sclerosis and symptoms thereof
AU2017232348A1 (en) 2016-03-15 2018-09-06 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer
CN109562116A (zh) 2016-05-18 2019-04-02 迪美公司 在癌症治疗中的双氢睾酮及双氢睾酮衍生物和促进剂
MX2019002673A (es) 2016-09-12 2019-07-04 Hoffman Steven Composiciones y metodos para tratar demencia.
BR112019009799A2 (pt) 2016-11-15 2019-08-06 Tyme Inc método para tratar câncer em um paciente
WO2018102506A1 (en) 2016-11-30 2018-06-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US11351136B2 (en) 2017-04-21 2022-06-07 Yamo Pharmaceuticals Llc Compositions and methods for treating retinopathy
WO2018204669A1 (en) 2017-05-03 2018-11-08 Nanobio Corporation Intravenous immunoglobulin compositions specific for respiratory syncytial virus and methods of making and using the same
CA3069703A1 (en) 2017-07-19 2019-01-24 Steven Hoffman Compositions for treating stress-related disorders
EP3681476B1 (en) 2017-09-15 2022-09-14 Tyme, Inc. Transdermal formulations
WO2019130637A1 (ja) 2017-12-28 2019-07-04 ジェイファーマ株式会社 がん治療薬
MX2021000314A (es) 2018-07-09 2021-03-25 Tyme Inc Formulaciones reductoras de tumores y metodos de uso de las mismas.
CN112584841A (zh) 2018-07-09 2021-03-30 迪美公司 肿瘤减小制剂及其使用方法
WO2020018292A1 (en) 2018-07-19 2020-01-23 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
WO2020112766A1 (en) 2018-11-26 2020-06-04 Steven Hoffman Compositions and methods for treating nerve agent exposure
CN110563602A (zh) 2018-12-26 2019-12-13 南宁多灵生物科技有限公司 迷迭香酸衍生物及其制备方法和应用
CN113710319B (zh) 2019-02-01 2024-10-11 霍夫曼技术有限责任公司 用于治疗焦虑相关病症的组合物和方法
US20200282014A1 (en) 2019-03-05 2020-09-10 Hoffman Technologies Llc Percutaneous anti-microbiota formulations
AU2020248716A1 (en) 2019-03-22 2021-11-04 Tyme, Inc. D-metyrosine compositions and methods for preparing same
EP3955910A4 (en) 2019-04-19 2023-01-25 Hoffman Technologies LLC. EXTENDED RELEASE FORMULATIONS
CA3140042A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US20220323551A1 (en) 2019-07-22 2022-10-13 Korea University Research And Business Foundation Composition for preventing, treating, or ameliorating viral infection disease, containing active oxygen production inhibitor and active oxygen scavenger complex as active ingredients
EP4045027A1 (en) 2019-10-15 2022-08-24 Tyme, Inc. Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
IL293706A (en) 2019-12-09 2022-08-01 Tyme Inc Pharmacy preparations and methods
CA3167918A1 (en) 2020-01-17 2021-07-22 Tyme, Inc. Compositions and methods for modulating cancer
EP4132561A4 (en) 2020-04-08 2024-04-24 Hoffman Technologies LLC METHODS FOR TREATING DISEASES CHARACTERIZED BY INSULIN DEFICIENCY IN ANIMALS
WO2021231931A1 (en) 2020-05-14 2021-11-18 Tyme, Inc. Methods of treating sars-cov-2 infections
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
EP4175938A1 (en) 2020-07-01 2023-05-10 Tyme, Inc. Crystalline forms of metyrosine

Also Published As

Publication number Publication date
EP3968785A4 (en) 2023-01-11
KR20220098682A (ko) 2022-07-12
EP3968785A1 (en) 2022-03-23
US20200360328A1 (en) 2020-11-19
US11534420B2 (en) 2022-12-27
CA3140042A1 (en) 2020-11-19
WO2020232227A1 (en) 2020-11-19
MX2021013901A (es) 2022-04-12
AU2020276605A1 (en) 2022-01-20
CN114173578A (zh) 2022-03-11
JP2022532210A (ja) 2022-07-13
BR112021022784A2 (pt) 2022-03-22
IL287982A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
EA202193111A1 (ru) Композиции и способы для лечения рака
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
EA202190630A1 (ru) Способы комбинированной терапии
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201890571A1 (ru) Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9)
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2022000027A (es) Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA202191630A1 (ru) ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA202091205A1 (ru) Композиции для терапии гипергликемии и сопутствующих состояний
SA519410324B1 (ar) صياغات رش إيبينيفرين
EA202092824A1 (ru) Комбинированная терапия
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения
EA202190798A1 (ru) Ротамерные изомеры 4-алкил-5-гетероарил-3h-1,2-дитиол-3-тионов